Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

A randomised trial of salsalate for insulin resistance and cardiovascular risk factors in persons with abnormal glucose tolerance.

Goldfine AB, Conlin PR, Halperin F, Koska J, Permana P, Schwenke D, Shoelson SE, Reaven PD.

Diabetologia. 2013 Apr;56(4):714-23. doi: 10.1007/s00125-012-2819-3. Epub 2013 Jan 31.

2.

The effect of salsalate on insulin action and glucose tolerance in obese non-diabetic patients: results of a randomised double-blind placebo-controlled study.

Koska J, Ortega E, Bunt JC, Gasser A, Impson J, Hanson RL, Forbes J, de Courten B, Krakoff J.

Diabetologia. 2009 Mar;52(3):385-93. doi: 10.1007/s00125-008-1239-x. Epub 2008 Dec 23.

3.

Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes.

Goldfine AB, Silver R, Aldhahi W, Cai D, Tatro E, Lee J, Shoelson SE.

Clin Transl Sci. 2008 May;1(1):36-43. doi: 10.1111/j.1752-8062.2008.00026.x.

4.

Effect of salsalate on insulin action, secretion, and clearance in nondiabetic, insulin-resistant individuals: a randomized, placebo-controlled study.

Kim SH, Liu A, Ariel D, Abbasi F, Lamendola C, Grove K, Tomasso V, Ochoa H, Reaven G.

Diabetes Care. 2014 Jul;37(7):1944-50. doi: 10.2337/dc13-2977.

5.

Salsalate improves glycemia and inflammatory parameters in obese young adults.

Fleischman A, Shoelson SE, Bernier R, Goldfine AB.

Diabetes Care. 2008 Feb;31(2):289-94. Epub 2007 Oct 24.

6.

Salsalate treatment improves glycemia without altering adipose tissue in nondiabetic obese hispanics.

Alderete TL, Sattler FR, Richey JM, Allayee H, Mittelman SD, Sheng X, Tucci J, Gyllenhammer LE, Grant EG, Goran MI.

Obesity (Silver Spring). 2015 Mar;23(3):543-51. doi: 10.1002/oby.20991. Epub 2015 Feb 3.

7.

Reduction of insulin resistance and plasma glucose level by salsalate treatment in persons with prediabetes.

Faghihimani E, Aminorroaya A, Rezvanian H, Adibi P, Ismail-Beigi F, Amini M.

Endocr Pract. 2012 Nov-Dec;18(6):826-33. doi: 10.4158/EP12064.OR.

PMID:
22784842
8.

Salsalate has no effect on insulin secretion but decreases insulin clearance: a randomized, placebo-controlled trial in subjects without diabetes.

Penesova A, Koska J, Ortega E, Bunt JC, Bogardus C, de Courten B.

Diabetes Obes Metab. 2015 Jun;17(6):608-12. doi: 10.1111/dom.12450. Epub 2015 Mar 12.

PMID:
25683256
9.

The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial.

Goldfine AB, Fonseca V, Jablonski KA, Pyle L, Staten MA, Shoelson SE; TINSAL-T2D (Targeting Inflammation Using Salsalate in Type 2 Diabetes) Study Team..

Ann Intern Med. 2010 Mar 16;152(6):346-57. doi: 10.7326/0003-4819-152-6-201003160-00004.

10.

Salicylate (salsalate) in patients with type 2 diabetes: a randomized trial.

Goldfine AB, Fonseca V, Jablonski KA, Chen YD, Tipton L, Staten MA, Shoelson SE; Targeting Inflammation Using Salsalate in Type 2 Diabetes Study Team..

Ann Intern Med. 2013 Jul 2;159(1):1-12. doi: 10.7326/0003-4819-159-1-201307020-00003.

11.

Pioglitazone improves glucose metabolism and modulates skeletal muscle TIMP-3-TACE dyad in type 2 diabetes mellitus: a randomised, double-blind, placebo-controlled, mechanistic study.

Tripathy D, Daniele G, Fiorentino TV, Perez-Cadena Z, Chavez-Velasquez A, Kamath S, Fanti P, Jenkinson C, Andreozzi F, Federici M, Gastaldelli A, Defronzo RA, Folli F.

Diabetologia. 2013 Oct;56(10):2153-63. doi: 10.1007/s00125-013-2976-z. Epub 2013 Jun 30.

PMID:
23811853
12.

Salsalate improves glycemic control in patients with newly diagnosed type 2 diabetes.

Faghihimani E, Aminorroaya A, Rezvanian H, Adibi P, Ismail-Beigi F, Amini M.

Acta Diabetol. 2013 Aug;50(4):537-43. doi: 10.1007/s00592-011-0329-2. Epub 2011 Sep 22.

PMID:
21938543
13.

Targeting inflammation using salsalate in patients with type 2 diabetes: effects on flow-mediated dilation (TINSAL-FMD).

Goldfine AB, Buck JS, Desouza C, Fonseca V, Chen YD, Shoelson SE, Jablonski KA, Creager MA; TINSAL-FMD (Targeting Inflammation Using Salsalate in Type 2 Diabetes–Flow-Mediated Dilation) Ancillary Study Team..

Diabetes Care. 2013 Dec;36(12):4132-9. doi: 10.2337/dc13-0859. Epub 2013 Oct 15.

14.

Antidiabetogenic effects of hydroxychloroquine on insulin sensitivity and beta cell function: a randomised trial.

Wasko MC, McClure CK, Kelsey SF, Huber K, Orchard T, Toledo FG.

Diabetologia. 2015 Oct;58(10):2336-43. doi: 10.1007/s00125-015-3689-2. Epub 2015 Jul 22.

15.

Chinese herbal medicine for impaired glucose tolerance: a randomized placebo controlled trial.

Grant SJ, Chang DH, Liu J, Wong V, Kiat H, Bensoussan A.

BMC Complement Altern Med. 2013 May 14;13:104. doi: 10.1186/1472-6882-13-104.

16.
17.

The impact of salsalate treatment on serum levels of advanced glycation end products in type 2 diabetes.

Barzilay JI, Jablonski KA, Fonseca V, Shoelson SE, Goldfine AB, Strauch C, Monnier VM; TINSAL-T2D Research Consortium..

Diabetes Care. 2014 Apr;37(4):1083-91. doi: 10.2337/dc13-1527. Epub 2013 Nov 19.

18.

Potential role of salicylates in type 2 diabetes.

Rumore MM, Kim KS.

Ann Pharmacother. 2010 Jul-Aug;44(7-8):1207-21. doi: 10.1345/aph.1M483. Epub 2010 Jun 1. Review.

PMID:
20516365
19.

Pancreatic beta cell function following liraglutide-augmented weight loss in individuals with prediabetes: analysis of a randomised, placebo-controlled study.

Kim SH, Liu A, Ariel D, Abbasi F, Lamendola C, Grove K, Tomasso V, Reaven G.

Diabetologia. 2014 Mar;57(3):455-62. doi: 10.1007/s00125-013-3134-3. Epub 2013 Dec 11.

20.

The effect of salsalate therapy on endothelial function in a broad range of subjects.

Nohria A, Kinlay S, Buck JS, Redline W, Copeland-Halperin R, Kim S, Beckman JA.

J Am Heart Assoc. 2014 Jan 3;3(1):e000609. doi: 10.1161/JAHA.113.000609.

Supplemental Content

Support Center